![Svante Rasmuson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Svante Rasmuson
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Svante Rasmuson tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Quintiles, Inc. (California)
![]() Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Medical/Nursing Services | Chief Executive Officer | |
MEDIGENE AG | Biotechnology | Corporate Officer/Principal | |
Artimplant AB
![]() Artimplant AB Medical SpecialtiesHealth Technology Artimplant AB engages in research and development of biomaterials for solutions to problems in orthopedic, odontological and reconstructive surgery. It also involves in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The company was founded by Anders Cedronius in 1990 and is headquartered in Vastra Frolunda, Sweden. | Medical Specialties | Director/Board Member | |
SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Operating Officer | |
Industrifonden
![]() Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investment Managers | Director of Investments Director/Board Member | |
University of Uppsala | College/University | Doctorate Degree | |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer | |
Arexis AB
![]() Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
TFS Trial Form Support AB
![]() TFS Trial Form Support AB Miscellaneous Commercial ServicesCommercial Services TFS Trial Form Support AB provides clinical trial services. The firm operates as a clinical contract research organization. Its services include regulatory affairs, feasibility, global clinical operations, study and site coordination, patient recruitment services, clinical data management, edc systems, biostatistics, pharmacovigilance/safety, medical writing, quality assurance, tfs academy, and functional service solutions. The company was founded by Daniel Spasic in 1996 and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Pharmacia Opthalmics, Inc. | Corporate Officer/Principal | ||
Aprea Therapeutics AB
![]() Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
PROMIMIC AB | Medical Specialties | Corporate Officer/Principal | |
BIOARCTIC AB | Pharmaceuticals: Major | Chairman | |
Dilafor AB
![]() Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Helicure AB
![]() Helicure AB Pharmaceuticals: MajorHealth Technology Helicure AB develops and manufactures vaccines. It operates as a biotech company that focuses on developing vaccines for prevention of gastric cancer caused by Helicobacter pylori, through active immunisation in infected patients with persistent dyspepsia. The company was founded by Thomas Borén and Lennart Hammarström in 2005 and is headquartered in Umea, Sweden. | Pharmaceuticals: Major | Chairman | |
Karlsruher Institut für Technologie | College/University | Doctorate Degree | |
Umecrine Cognition AB
![]() Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman | |
ClanoTech AB
![]() ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Smartfish AS
![]() Smartfish AS Food RetailRetail Trade Smartfish AS is a holding company that creates drinks for special medical purposes, as well as for people on the go and top athletes to improve their recovery and immune response. It is a research-based company that develops omega 3 based emulsions for brain health, heart health, immune system, and recovery. The firm’s product NutriFriend medical nutrition is sold through pharmacies, medical wholesalers, and directly to hospitals. The company was founded by Janne Sande Mathisen and Henrik Mathisen in 2001 and is headquartered in Oslo, Norway. | Food Retail | Director/Board Member | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Corporate Officer/Principal Chief Executive Officer | |
Aprea Personal AB | Chairman | ||
Neoventa Holding AB
![]() Neoventa Holding AB MiscellaneousMiscellaneous Neoventa Holding AB invests in companies with interests in development and marketing of monitoring and control equipment for perinatal care. The company is headquartered in Molndal, Sweden. | Miscellaneous | Director/Board Member | |
InDex Diagnostics AB
![]() InDex Diagnostics AB Pharmaceuticals: MajorHealth Technology Part of InDex Pharmaceuticals Holding AB, InDex Diagnostics AB manufactures pharmaceutical products. The company is based in Solna, Sweden. Peter Hakim Zerhouni has been the CEO of the Swedish company since 2015. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Chairman | |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman | |
KDev Investments AB
![]() KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Chairman | |
Forendo Pharma Oy
![]() Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member | |
Nuevolution A/S
![]() Nuevolution A/S Miscellaneous Commercial ServicesCommercial Services Nuevolution A/S engages in research and experimental development on biotechnology. It produces and commercializes technologies for the manufacture of substances for use in the pharmaceutical industry by screening non-biological polymers and low-molecular substances. The company was founded on May 8, 2001 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member | |
Airsonett Holding AB | Corporate Officer/Principal Director/Board Member | ||
Svenska Vaccinfabriken Produktion AB
![]() Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
InDex Pharmaceuticals AB
![]() InDex Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Chief Executive Officer | |
Smartfish AB
![]() Smartfish AB Beverages: Non-AlcoholicConsumer Non-Durables Part of Smartfish AS, Smartfish AB is a Swedish company that focuses on medical nutrition for cancer patients. The company is based in Solna, Sweden. The company believes that good nutritional status is crucial for successful treatment and optimal outcomes. Smartfish has a slim and flexible organizational structure and aims to grow through strategic relationships with leading R&D, production, and distribution partners. The company's medical nutrition products are used to improve the nutritional status of malnourished or undernourished patients. | Beverages: Non-Alcoholic | Chairman | |
Rolfsen Consulting AB | Chief Executive Officer | ||
Cinclus Pharma AG
![]() Cinclus Pharma AG BiotechnologyHealth Technology Cinclus Pharma AG is a Swiss Swedish pharmaceutical company founded in 2011. Cinclus Pharma is based in Basel, Switzerland. The private company is focused on bringing relief to people suffering from gastric acid related diseases, particularly gastroesophageal reflux disease (GERD). Cinclus Pharma's clinical stage drug candidate, linaprazan glurate, is a new approach to managing GERD and is showing promising results in acid control and lowering the cmax-value. The company was founded by experts in the field of GERD treatment with extensive experience from Astra and Astra Zeneca. | Biotechnology | Director/Board Member Director/Board Member | |
Serendipity Partners, Inc. | Miscellaneous | Corporate Officer/Principal | |
Serendipity Partners
![]() Serendipity Partners Investment ManagersFinance Serendipity Partners Management AS (Serendipity Partners) is a private equity/venture capital firm founded in 2015 by Michael Bodd. The firm is headquartered in Oslo, Norway. | Investment Managers | Private Equity Investor | |
Cinclus Pharma Holding AB
![]() Cinclus Pharma Holding AB BiotechnologyHealth Technology Cinclus Pharma Holding AB is a Swedish pharmaceutical company that focuses on developing clinical stage drug candidates for gastric acid related diseases. The company's drug candidate, linaprazan glurate, takes a new approach to provide improved management of GERD. Gastroesophageal reflux disease, or acid reflux, is a condition in which the content of the stomach regurgitates into the esophagus. The company was founded by pioneers in GERD treatment with extensive experience from Astra and Astra Zeneca. Christer Ahlberg has been the CEO of the company since 2021. | Biotechnology | Chairman Director/Board Member | |
Ovegun AB | Director/Board Member | ||
Kanalfläkt Design Alluiq AB
![]() Kanalfläkt Design Alluiq AB Medical SpecialtiesHealth Technology Kanalfläkt Design Alluiq AB is a private company based in Skinnskatteberg, Sweden. The Swedish company manufactures medical and dental instruments. | Medical Specialties | Director/Board Member | |
Sjöängensbrygga Ekonomisk Förening | Director/Board Member | ||
Dilafor Incentive AB | Director/Board Member | ||
Uc Research AB | Director/Board Member |
Statistiche
Distribuzione geografica
Svezia | 40 |
Norvegia | 4 |
Stati Uniti | 3 |
Germania | 3 |
Regno Unito | 2 |
Settori
Health Technology | 26 |
Commercial Services | 6 |
Finance | 5 |
Consumer Services | 3 |
Miscellaneous | 3 |
Posizioni
Director/Board Member | 84 |
Chairman | 24 |
Corporate Officer/Principal | 24 |
Independent Dir/Board Member | 15 |
Chief Executive Officer | 10 |
Contatti più connessi
- Borsa valori
- Insiders
- Svante Rasmuson
- Connessioni Società